

1 **Supplemental Table 1. Baseline characteristics according to initial decline in eGFR ($\geq 15\%$) and treatment assignment**

	No decline in eGFR		Initial decline in eGFR $\geq 15\%$		p-value
	Placebo N=2,415	Finerenone N=2,154	Placebo N=374	Finerenone N=644	
Age (years)	71.8 \pm 9.7	71.5 \pm 9.7	72.5 \pm 9.8	73.1 \pm 9.3	<0.01
Age>70 years	1,433 (59.3)	1,261 (58.5)	231 (61.8)	410 (63.7)	0.10
Male	1,312 (54.3)	1,230 (57.1)	208 (55.6)	327 (50.8)	0.03
Region					<0.01
Western Europe, Oceania and Others	488 (20.2)	390 (18.1)	86 (23.0)	166 (25.8)	
Eastern Europe	1,082 (44.8)	995 (46.2)	158 (42.2)	266 (41.3)	
Asia	410 (17.0)	373 (17.3)	50 (13.4)	91 (14.1)	
North America	183 (7.6)	155 (7.2)	32 (8.6)	55 (8.5)	
Latin America	252 (10.4)	241 (11.2)	48 (12.8)	66 (10.2)	
Race					0.25
White	1,897 (78.6)	1,669 (77.5)	302 (80.7)	524 (81.4)	
Black	30 (1.2)	34 (1.6)	7 (1.9)	13 (2.0)	
Asian	416 (17.2)	376 (17.5)	52 (13.9)	92 (14.3)	
Other	72 (3.0)	75 (3.5)	13 (3.5)	15 (2.3)	
NYHA III or IV	726 (30.1)	635 (29.5)	132 (35.3)	218 (33.9)	0.03
KCCQ-OSS	62.9 \pm 22.5	64.3 \pm 21.6	60.3 \pm 22.7	60.4 \pm 22.7	<0.001
KCCQ-CSS	65.3 \pm 22.7	67.1 \pm 21.8	62.5 \pm 22.5	62.6 \pm 23.2	<0.001
BMI (kg/m ²)	30.1 \pm 6.1	29.8 \pm 6.1	29.7 \pm 6.2	30.0 \pm 6.0	0.28
BMI category					0.58
<18.5	24 (1.0)	26 (1.2)	5 (1.3)	5 (0.8)	
18.5-24.9	478 (19.8)	455 (21.2)	84 (22.5)	130 (20.2)	
25-29.9	789 (32.7)	713 (33.2)	131 (35.1)	220 (34.2)	
30-34.4	647 (26.8)	567 (26.4)	82 (22.0)	154 (24.0)	
≥ 35	472 (19.6)	388 (18.1)	71 (19.0)	134 (20.8)	
Heart rate (bpm)	71.1 \pm 11.8	71.6 \pm 11.7	71.4 \pm 12.0	71.8 \pm 11.8	0.48
Systolic blood pressure (mmHg)	129.2 \pm 15.2	128.8 \pm 15.3	130.4 \pm 15.5	131.6 \pm 15.3	<0.001

Systolic blood pressure >140 mmHg	547 (22.7)	481 (22.3)	85 (22.7)	177 (27.5)	0.04
Diastolic Blood Pressure (mmHg)	75.3±10.4	75.7±10.2	75.9±10.6	76.0±10.5	0.37
LVEF (%)	52.5±7.8	52.5±7.8	52.5±7.9	53.2±8.0	0.25
LVEF ≥50%	1,541 (63.8)	1,342 (62.4)	248 (66.3)	425 (66.0)	0.26
LVEF ≥60%	459 (19.0)	412 (19.2)	71 (19.0)	128 (19.9)	0.97
History of LVEF <40%	102 (4.2)	111 (5.2)	12 (3.2)	25 (3.9)	0.20
eGFR (ml/min/1.73m ²)	62.3±20.4	62.0±19.7	63.1±18.3	62.2±18.1	0.82
eGFR <60 ml/min/1.73m ²	1,163 (48.2)	1,051 (48.8)	163 (43.6)	296 (46.0)	0.21
eGFR <45 ml/min/1.73m ²	568 (23.5)	455 (21.1)	67 (17.9)	135 (21.0)	0.04
Baseline UACR (mg/g)	18.0 (6.2-60.5)	16.0 (6.0-63.0)	22.0 (7.0-99.0)	24.0 (8.8-80.0)	<0.001
UACR category					<0.001
<30	1,437 (61.4)	1,319 (63.3)	200 (55.4)	340 (54.2)	
30-299	688 (29.4)	563 (27.0)	115 (31.9)	218 (34.8)	
≥300	215 (9.2)	203 (9.7)	46 (12.7)	69 (11.0)	
Potassium (mmol/L)	4.4 (4.1-4.7)	4.4 (4.1-4.7)	4.4 (4.1-4.7)	4.3 (4.0-4.6)	0.14
Hemoglobin (g/dL)	13.5 (12.3-14.5)	13.5 (12.4-14.6)	13.0 (11.8-14.3)	13.2 (12.0-14.3)	<0.001
Anemia	600 (26.3)	528 (25.7)	134 (38.2)	189 (31.3)	<0.001
NT-proBNP (pg/ml)	986 (414-1859)	1008 (434-1870)	1212 (509-2521)	1160 (597-2237)	<0.001
- No atrial fibrillation	560 (300-1238)	556 (295-1196)	652 (339-1645)	787 (413-1454)	<0.001
- Atrial fibrillation	1682 (1097-2675)	1711 (1163-2739)	1948 (1300-3325)	1786 (1157-2849)	0.03
Medical history					
Prior hospitalization for HF	1,449 (60.0)	1,281 (59.5)	234 (62.6)	383 (59.5)	0.72
Type 2 diabetes mellitus*	993 (41.2)	880 (40.9)	155 (41.7)	255 (39.7)	0.91
Hypertension	2,176 (90.1)	1,879 (87.2)	334 (89.3)	576 (89.4)	0.02
Myocardial infarction	604 (25.0)	588 (27.3)	107 (28.6)	150 (23.3)	0.08
CABG	371 (15.4)	332 (15.4)	57 (15.2)	100 (15.5)	0.99
PCI	586 (24.3)	550 (25.5)	94 (25.1)	137 (21.3)	0.17
Peripheral arterial disease	212 (8.8)	179 (8.3)	39 (10.4)	73 (11.3)	0.09
Atrial fibrillation	1,311 (54.3)	1,131 (52.5)	195 (52.1)	392 (60.9)	<0.01
COPD	312 (12.9)	270 (12.5)	51 (13.6)	77 (12.0)	0.86

Stroke	312 (12.9)	312 (14.5)	61 (16.3)	92 (14.3)	0.22
Treatment					
ACE-I	869 (36.0)	786 (36.5)	135 (36.1)	229 (35.6)	0.97
ACE-I or ARB	1,717 (71.1)	1,516 (70.4)	274 (73.3)	479 (74.4)	0.20
Sacubitril/valsartan	212 (8.8)	188 (8.7)	21 (5.6)	45 (7.0)	0.10
Beta-blocker	2,049 (84.8)	1,837 (85.3)	336 (89.8)	539 (83.7)	0.05
SGLT2 inhibitor	350 (14.5)	277 (12.9)	53 (14.2)	87 (13.5)	0.45
Loop diuretics	2,113 (87.5)	1,867 (86.7)	322 (86.1)	571 (88.7)	0.50
Thiazide	316 (13.1)	303 (14.1)	59 (15.8)	94 (14.6)	0.43
Digoxin	176 (7.3)	172 (8.0)	33 (8.8)	53 (8.2)	0.64
Amiodarone	191 (100.0)	144 (100.0)	36 (100.0)	66 (100.0)	
Calcium channel blocker	813 (33.7)	656 (30.5)	141 (37.7)	235 (36.5)	<0.01
Pacemaker	141 (5.8)	114 (5.3)	19 (5.1)	37 (5.7)	0.84

2 *Type 1 diabetes was excluded in this analysis

3 **without ARNI

4

5 Abbreviations: ACE-I, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor blocker and neprilysin
6 inhibitor; BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; eGFR, estimated
7 glomerular filtration rate; HF, heart failure; KCCQ-OSS, Kansas City Cardiomyopathy Questionnaire-overall summary score; -CSS, -clinical
8 summary score; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart
9 Association functional classification; PCI, percutaneous coronary intervention; SGLT2, sodium-glucose cotransporter 2; UACR, urine albumin-
10 creatinine ratio

11

12 **Supplemental Table 2. Absolute changes in eGFR according to baseline background treatment**

	No treatment		On treatment		P for Interaction
	Placebo	Finerenone	Placebo	Finerenone	
ACE-I					
Mean change from baseline to 1 month (95% CI) (ml/min/1.73m ²)	-0.19 (-0.63 to 0.25)	-2.81 (-3.30 to -2.32)	-0.44 (-1.04 to 0.15)	-2.55 (-3.22 to -1.88)	
Mean difference* (95% CI) (ml/min/1.73m ²)	-2.65 (-3.28 to -2.02)		-2.21 (-3.07 to -1.34)		0.41
ARB					
Mean change from baseline to 1 month (95% CI) (ml/min/1.73m ²)	-0.35 (-0.82 to 0.12)	-2.46 (-2.96 to -1.95)	-0.20 (-0.73 to 0.34)	-3.05 (-3.67 to -2.42)	
Mean difference* (95% CI) (ml/min/1.73m ²)	-2.14 (-2.81 to -1.48)		-2.96 (-3.75 to -2.17)		0.13
ARNI					
Mean change from baseline to 1 month (95% CI) (ml/min/1.73m ²)	-0.26 (-0.63 to 0.11)	-2.74 (-3.15 to -2.33)	-0.52 (-1.59 to 0.54)	-2.43 (-3.78 to -1.07)	
Mean difference* (95% CI) (ml/min/1.73m ²)	-2.53 (-3.07 to -2.00)		-1.94 (-3.64 to -0.25)		0.62
SGLT2i					
Mean change from baseline to 1 month (95% CI) (ml/min/1.73m ²)	-0.38 (-0.77 to 0.00)	-2.67 (-3.10 to -2.25)	0.33 (-0.54 to 1.20)	-2.99 (-4.07 to -1.91)	
Mean difference* (95% CI) (ml/min/1.73m ²)	-2.34 (-2.93 to -1.83)		-3.19 (-4.54 to -1.85)		0.31

14 **Supplemental Table 3. Absolute changes in eGFR in ambulatory and hospitalized patients**

	Ambulatory patients		Hospitalized patients		P for Interaction
	Placebo	Finerenone	Placebo	Finerenone	
Mean change from baseline to 1 month (95% CI) (ml/min/1.73m ²)	-0.57 (-0.92 to -0.22)	-2.96 (-3.35 to -2.56)	2.22 (0.70 to 3.76)	-0.76 (-2.41 to 0.89)	
Mean difference* (95% CI) (ml/min/1.73m ²)	-2.45 (-2.96 to -1.94)		-2.74 (-4.86 to -0.62)		0.61

15

16

17 **Supplemental Table 4. Change in UACR from baseline to 1 month according to the initial decline in eGFR \geq 15% and treatment**
 18 **assignment**

	No initial eGFR decline		Initial decline in eGFR \geq 15%		P for Interaction
	Placebo	Finerenone	Placebo	Finerenone	
Mean change from baseline to 1 month (95% CI) (ml/min/1.73m ²)	11 (-9 to 31)	-21 (-34 to -8)	-37 (-81 to 8)	-72 (-112 to -32)	
Mean difference* (95% CI) (ml/min/1.73m ²)	-33 (-57 to -10)		-52 (-105 to 1)		0.67

20 **Supplemental Table 5. Early decline in kidney function at 1 month and the subsequent occurrence of total heart failure events in each**
 21 **treatment group (landmark analysis)**

	Placebo		Finerenone		p-value for interaction
	No decline	Decline in kidney function	No decline	Decline in kidney function	
Changes in eGFR					
≥15% decline in eGFR					
Event rate per 100 person-y (95% CI)	12.6 (11.2-14.1)	19.2 (14.7-25.2)	10.1 (8.8-11.6)	13.5 (10.8-16.8)	
RR (95% CI)	Reference	1.51 (1.13-2.01)	Reference	1.22 (0.95-1.58)	0.29
Adjusted RR* (95% CI)	Reference	1.48 (1.14-1.94)	Reference	1.13 (0.86-1.48)	0.19
≥30% decline in eGFR					
Event rate per 100 person-y (95% CI)	13.3 (11.9-14.8)	21.7 (13.1-36.0)	10.5 (9.3-11.8)	19.1 (12.2-29.9)	
RR (95% CI)	Reference	1.72 (1.05-2.80)	Reference	1.63 (1.03-2.58)	0.81
Adjusted RR* (95% CI)	Reference	1.46 (0.86-2.49)	Reference	1.08 (0.64-1.83)	0.38
≥5 ml/min/1.73m² decline in eGFR					
Event rate per 100 person-y (95% CI)	13.5 (12.0-15.3)	13.2 (10.8-16.2)	9.8 (8.5-11.2)	12.6 (10.4-15.3)	
RR (95% CI)	Reference	0.99 (0.78-1.24)	Reference	1.21 (0.96-1.53)	0.19
Adjusted RR* (95% CI)	Reference	1.17 (0.93-1.49)	Reference	1.28 (1.00-1.64)	0.80
≥10 ml/min/1.73m² decline in eGFR					
Event rate per 100 person-y (95% CI)	13.3 (11.9-14.9)	14.2 (10.7-18.7)	11.0 (9.7-12.5)	10.3 (7.9-13.5)	
RR (95% CI)	Reference	1.14 (0.84-1.53)	Reference	0.91 (0.68-1.22)	0.27
Adjusted RR* (95% CI)	Reference	1.36 (1.00-1.84)	Reference	0.98 (0.70-1.35)	0.07
Changes in creatinine					
≥15% increase in creatinine					
Event rate per 100 person-y (95% CI)	12.7 (11.3-14.2)	18.1 (13.9-23.6)	10.3 (9.0-11.8)	12.5 (10.0-15.6)	
RR (95% CI)	Reference	1.42 (1.07-1.87)	Reference	1.09 (0.84-1.40)	0.18
Adjusted RR* (95% CI)	Reference	1.50 (1.15-1.95)	Reference	1.06 (0.81-1.39)	0.08
≥30% increase in creatinine					
Event rate per 100 person-y (95% CI)	13.1 (11.8-14.6)	24.5 (15.2-39.4)	10.5 (9.3-11.9)	15.5 (10.3-23.4)	
RR (95% CI)	Reference	1.90 (1.19-3.03)	Reference	1.36 (0.89-2.07)	0.25

Adjusted RR* (95% CI)	Reference	1.72 (1.10-2.70)	Reference	1.00 (0.62-1.61)	0.73
≥0.3 mg/dL increase in creatinine					
Event rate per 100 person-y (95% CI)	12.7 (11.4-14.2)	32.3 (21.7-48.0)	9.9 (8.7-11.2)	22.6 (16.4-31.3)	
RR (95% CI)	Reference	2.41 (1.61-3.60)	Reference	1.92 (1.36-2.72)	0.44
Adjusted RR* (95% CI)	Reference	1.77 (1.22-2.56)	Reference	1.30 (0.90-1.89)	0.39
≥0.5 mg/dL increase in creatinine					
Event rate per 100 person-y (95% CI)	13.2 (11.8-14.6)	34.1 (19.7-59.2)	10.5 (9.4-11.9)	23.1 (13.2-40.3)	
RR (95% CI)	Reference	2.69 (1.61-4.48)	Reference	1.95 (1.09-3.51)	0.32
Adjusted RR* (95% CI)	Reference	2.08 (1.17-3.71)	Reference	0.93 (0.49-1.77)	0.06

22

23

24 **Supplemental Table 6. Early decline in kidney function at 1 month and the subsequent occurrence of cardiovascular death in each**
 25 **treatment group (landmark analysis)**

	Placebo		Finerenone		p-value for interaction
	No decline	Decline in kidney function	No decline	Decline in kidney function	
Changes in eGFR					
≥15% decline in eGFR					
Event rate per 100 person-y (95% CI)	3.3 (2.8-3.8)	6.0 (4.6-7.9)	3.4 (2.9-3.9)	2.9 (2.2-3.9)	
RR (95% CI)	Reference	1.78 (1.30-2.43)	Reference	0.87 (0.62-1.21)	0.001
Adjusted RR* (95% CI)	Reference	1.64 (1.20-2.26)	Reference	0.85 (0.61-1.21)	<0.01
≥30% decline in eGFR					
Event rate per 100 person-y (95% CI)	3.5 (3.1-4.0)	8.3 (4.5-15.5)	3.3 (2.9-3.8)	2.0 (0.9-4.4)	
RR (95% CI)	Reference	2.14 (1.13-4.06)	Reference	0.61 (0.27-1.38)	0.01
Adjusted RR* (95% CI)	Reference	1.78 (0.90-3.51)	Reference	0.50 (0.22-1.15)	<0.01
≥5 ml/min/1.73m² decline in eGFR					
Event rate per 100 person-y (95% CI)	3.3 (2.8-3.8)	4.5 (3.7-5.6)	3.5 (3.0-4.2)	2.8 (2.2-3.6)	
RR (95% CI)	Reference	1.36 (1.04-1.79)	Reference	0.81 (0.61-1.07)	<0.01
Adjusted RR* (95% CI)	Reference	1.60 (1.20-2.12)	Reference	0.84 (0.62-1.14)	<0.001
≥10 ml/min/1.73m² decline in eGFR					
Event rate per 100 person-y (95% CI)	3.3 (2.9-3.8)	5.8 (4.3-7.8)	3.4 (2.9-3.9)	2.7 (2.0-3.8)	
RR (95% CI)	Reference	1.72 (1.23-2.39)	Reference	0.80 (0.56-1.15)	<0.01
Adjusted RR* (95% CI)	Reference	1.97 (1.39-2.78)	Reference	0.94 (0.65-1.38)	<0.01
Changes in creatinine					
≥15% increase in creatinine					
Event rate per 100 person-y (95% CI)	3.3 (2.9-3.8)	5.5 (4.2-7.3)	3.4 (2.9-3.9)	2.8 (2.1-3.8)	
RR (95% CI)	Reference	1.62 (1.19-2.22)	Reference	0.84 (0.60-1.16)	<0.01
Adjusted RR* (95% CI)	Reference	1.58 (1.14-2.19)	Reference	0.82 (0.58-1.15)	<0.01
≥30% increase in creatinine					
Event rate per 100 person-y (95% CI)	3.5 (3.0-3.9)	9.0 (5.5-14.8)	3.4 (2.9-3.8)	1.9 (0.9-3.7)	
RR (95% CI)	Reference	2.43 (1.46-4.06)	Reference	0.56 (0.28-1.14)	<0.001

Adjusted RR* (95% CI)	Reference	2.18 (1.28-3.71)	Reference	0.43 (0.20-0.93)	<0.001
≥0.3 mg/dL increase in creatinine					
Event rate per 100 person-y (95% CI)	3.4 (3.0-3.9)	8.9 (5.8-13.7)	3.3 (2.8-3.8)	3.2 (1.9-5.1)	
RR (95% CI)	Reference	2.42 (1.54-3.82)	Reference	0.96 (0.57-1.60)	<0.01
Adjusted RR* (95% CI)	Reference	1.76 (1.09-2.83)	Reference	0.67 (0.40-1.14)	<0.01
≥0.5 mg/dL increase in creatinine					
Event rate per 100 person-y (95% CI)	3.6 (3.1-4.1)	7.1 (3.2-15.8)	3.3 (2.9-3.8)	1.8 (0.6-5.7)	
RR (95% CI)	Reference	1.82 (0.80-4.11)	Reference	0.56 (0.18-1.76)	0.08
Adjusted RR* (95% CI)	Reference	1.54 (0.67-3.52)	Reference	0.33 (0.10-1.04)	0.02

27 **Supplemental Table 7. Early decline in kidney function at 1 month and subsequent first heart failure event or cardiovascular death in**
 28 **each treatment group (landmark analysis)**

	Placebo		Finerenone		p-value for interaction
	No decline	Decline in kidney function	No decline	Decline in kidney function	
Changes in eGFR					
≥15% decline in eGFR					
RR (95% CI)	Reference	1.34 (1.08-1.66)	Reference	1.05 (0.86-1.28)	0.08
Adjusted RR* (95% CI)	Reference	1.28 (1.03-1.59)	Reference	0.98 (0.80-1.20)	0.04
≥30% decline in eGFR					
RR (95% CI)	Reference	1.31 (0.77-2.23)	Reference	1.10 (0.75-1.61)	0.48
Adjusted RR* (95% CI)	Reference	1.06 (0.61-1.85)	Reference	0.76 (0.50-1.14)	0.26
≥5 ml/min/1.73m² decline in eGFR					
RR (95% CI)	Reference	1.03 (0.86-1.23)	Reference	0.95 (0.80-1.13)	0.55
Adjusted RR* (95% CI)	Reference	1.15 (0.96-1.38)	Reference	0.97 (0.80-1.17)	0.09
≥10 ml/min/1.73m² decline in eGFR					
RR (95% CI)	Reference	1.18 (0.93-1.50)	Reference	0.86 (0.69-1.08)	<0.05
Adjusted RR* (95% CI)	Reference	1.35 (1.05-1.73)	Reference	0.91 (0.72-1.15)	<0.01
Changes in creatinine					
≥15% increase in creatinine					
RR (95% CI)	Reference	1.28 (1.04-1.58)	Reference	1.00 (0.82-1.22)	0.08
Adjusted RR* (95% CI)	Reference	1.32 (1.06-1.64)	Reference	0.96 (0.78-1.19)	0.02
≥30% increase in creatinine					
RR (95% CI)	Reference	1.58 (1.06-2.37)	Reference	0.97 (0.69-1.37)	<0.05
Adjusted RR* (95% CI)	Reference	1.44 (0.95-2.18)	Reference	0.71 (0.49-1.03)	<0.01
≥0.3 mg/dL increase in creatinine					
RR (95% CI)	Reference	1.92 (1.39-2.65)	Reference	1.32 (0.99-1.74)	0.06
Adjusted RR* (95% CI)	Reference	1.44 (1.03-2.02)	Reference	0.91 (0.68-1.22)	0.04
≥0.5 mg/dL increase in creatinine					
RR (95% CI)	Reference	1.63 (0.90-2.99)	Reference	1.40 (0.88-2.22)	0.53

Adjusted RR* (95% CI)	Reference	1.25 (0.68-2.30)	Reference	0.75 (0.46-1.21)	0.17
29					
30					

31 **Supplemental Table 8. Early decline in kidney function at 1 month and subsequent first heart failure event or cardiovascular death in**
 32 **each treatment group (landmark analysis with competing risk of death)**

	Placebo		Finerenone		p-value for interaction
	No decline	Decline in kidney function	No decline	Decline in kidney function	
Changes in eGFR					
≥15% decline in eGFR					
RR (95% CI)	Reference	1.34 (1.08-1.67)	Reference	1.04 (0.85-1.26)	0.07
Adjusted RR* (95% CI)	Reference	1.31 (1.05-1.64)	Reference	0.97 (0.79-1.20)	0.04
≥30% decline in eGFR					
RR (95% CI)	Reference	1.29 (0.75-2.24)	Reference	1.03 (0.70-1.51)	0.45
Adjusted RR* (95% CI)	Reference	1.00 (0.53-1.88)	Reference	0.74 (0.48-1.14)	0.39
≥5 ml/min/1.73m² decline in eGFR					
RR (95% CI)	Reference	1.04 (0.87-1.23)	Reference	0.95 (0.80-1.13)	0.47
Adjusted RR* (95% CI)	Reference	1.18 (0.98-1.43)	Reference	0.97 (0.80-1.17)	0.08
≥10 ml/min/1.73m² decline in eGFR					
RR (95% CI)	Reference	1.17 (0.92-1.48)	Reference	0.85 (0.69-1.06)	0.05
Adjusted RR* (95% CI)	Reference	1.33 (1.03-1.72)	Reference	0.90 (0.70-1.14)	<0.01
Changes in creatinine					
≥15% increase in creatinine					
RR (95% CI)	Reference	1.29 (1.04-1.60)	Reference	0.99 (0.82-1.21)	0.06
Adjusted RR* (95% CI)	Reference	1.35 (1.08-1.69)	Reference	0.96 (0.77-1.18)	0.02
≥30% increase in creatinine					
RR (95% CI)	Reference	1.60 (1.05-2.43)	Reference	0.93 (0.65-1.31)	0.04
Adjusted RR* (95% CI)	Reference	1.40 (0.88-2.23)	Reference	0.70 (0.47-1.04)	0.02
≥0.3 mg/dL increase in creatinine					
RR (95% CI)	Reference	1.92 (1.37-2.70)	Reference	1.25 (0.94-1.67)	<0.05
Adjusted RR* (95% CI)	Reference	1.44 (0.99-2.10)	Reference	0.89 (0.66-1.22)	0.06
≥0.5 mg/dL increase in creatinine					
RR (95% CI)	Reference	1.58 (0.84-2.99)	Reference	1.26 (0.78-2.04)	0.53

Adjusted RR* (95% CI)	Reference	1.14 (0.55-2.40)	Reference	0.71 (0.42-1.22)	0.32
33					
34					

35 **Supplemental Table 9. Early decline in kidney function at 1 month and the subsequent primary outcome in each treatment group (using**
 36 **imputed data)**

	Placebo		Finerenone		p-value for interaction
	No decline	Decline in kidney function	No decline	Decline in kidney function	
Changes in eGFR					
≥15% decline in eGFR					
RR (95% CI)	Reference	1.55 (1.24-1.95)	Reference	1.13 (0.91-1.41)	<0.05
Adjusted RR* (95% CI)	Reference	1.52 (1.22-1.88)	Reference	1.07 (0.86-1.34)	0.02
≥30% decline in eGFR					
RR (95% CI)	Reference	1.80 (1.22-2.65)	Reference	1.22 (0.78-1.91)	0.16
Adjusted RR* (95% CI)	Reference	1.63 (1.08-2.46)	Reference	0.93 (0.57-1.51)	0.05
≥5 ml/min/1.73m² decline in eGFR					
RR (95% CI)	Reference	1.07 (0.89-1.29)	Reference	1.08 (0.89-1.32)	0.91
Adjusted RR* (95% CI)	Reference	1.27 (1.04-1.55)	Reference	1.18 (0.96-1.45)	0.32
≥10 ml/min/1.73m² decline in eGFR					
RR (95% CI)	Reference	1.25 (0.99-1.58)	Reference	0.91 (0.71-1.15)	<0.05
Adjusted RR* (95% CI)	Reference	1.51 (1.18-1.92)	Reference	0.99 (0.76-1.30)	<0.01
Changes in creatinine					
15% increase in creatinine					
RR (95% CI)	Reference	1.42 (1.14-1.77)	Reference	1.02 (0.83-1.27)	0.04
Adjusted RR* (95% CI)	Reference	1.49 (1.20-1.85)	Reference	1.00 (0.80-1.26)	<0.01
30% increase in creatinine					
RR (95% CI)	Reference	1.75 (1.25-2.45)	Reference	1.23 (0.87-1.73)	0.11
Adjusted RR* (95% CI)	Reference	1.65 (1.17-2.34)	Reference	0.99 (0.68-1.44)	0.02
≥0.3 mg/dL increase in creatinine					
RR (95% CI)	Reference	2.19 (1.61-2.97)	Reference	1.66 (1.23-2.24)	0.21
Adjusted RR* (95% CI)	Reference	1.73 (1.29-2.32)	Reference	1.18 (0.86-1.60)	0.09
≥0.5 mg/dL increase in creatinine					
RR (95% CI)	Reference	2.43 (1.55-3.83)	Reference	1.51 (0.87-2.60)	0.12

Adjusted RR* (95% CI)

Reference

2.04 (1.23-3.37)

Reference

0.81 (0.45-1.44)

0.01

Supplemental Table 10. Association between finerenone use and adjusted risk for the primary outcome according to initial changes in renal function (landmark per-protocol analysis)


	No initial decline in renal function		Initial decline in renal function		p-value for interaction
	Placebo	Finerenone	Placebo	Finerenone	
Changes in eGFR					
≥15% decline in eGFR					
Adjusted RR (95% CI)	Reference	0.64 (0.54-0.76)	Reference	0.55 (0.40-0.76)	0.37
≥30% decline in eGFR					
Adjusted RR (95% CI)	Reference	0.65 (0.56-0.75)	Reference	0.30 (0.14-0.65)	0.33
≥5 ml/min/1.73m² decline in eGFR					
Adjusted RR (95% CI)	Reference	0.65 (0.54-0.77)	Reference	0.58 (0.44-0.75)	0.57
≥10 ml/min/1.73m² decline in eGFR					
Adjusted RR (95% CI)	Reference	0.66 (0.56-0.78)	Reference	0.44 (0.30-0.64)	0.10
Changes in creatinine					
15% increase in creatinine					
Adjusted RR (95% CI)	Reference	0.67 (0.57-0.79)	Reference	0.49 (0.36-0.68)	0.09
30% increase in creatinine					
Adjusted RR (95% CI)	Reference	0.66 (0.57-0.77)	Reference	0.32 (0.18-0.56)	0.04
≥0.3 mg/dL increase in creatinine					
Adjusted RR (95% CI)	Reference	0.63 (0.54-0.74)	Reference	0.58 (0.36-0.92)	0.63
≥0.5 mg/dL increase in creatinine					
Adjusted RR (95% CI)	Reference	0.65 (0.56-0.75)	Reference	0.34 (0.15-0.75)	0.22


Supplemental Table 11. Study drug discontinuation at any time point and subsequent outcomes (time-updated Cox model)

	Placebo		Finerenone		p-value for interaction
	No discontinuation (N=1,952)	Discontinuation at any time point (N=837)	No discontinuation (N=1,977)	Discontinuation at any time point (N=819)	
Total HF events and CV death					
Event rate per 100 person-y (95% CI)	15.3 (13.9-16.9)	34.8 (29.7-40.8)	10.5 (9.4-11.7)	42.7 (36.7-49.6)	
RR (95% CI)	Reference	2.44 (2.03-2.93)	Reference	4.56 (3.84-5.42)	<0.001
Adjusted RR (95% CI)	Reference	1.93 (1.60-2.32)	Reference	4.05 (3.37-4.86)	<0.001

All analyses were restricted to the patients who received at least one dose of the study drug.


Supplemental Figure 1. Change in eGFR according to initial decline in eGFR and treatment assignment





New Supplemental Figure 2. Change in NT-proBNP according to initial decline in eGFR $\geq 15\%$ and treatment assignment

Supplemental Figure 3. Effect of finerenone compared to placebo across absolute change in eGFR from baseline to 1 month



Supplemental Figure 4. Incidence rate of the primary outcome across the range of percent change in eGFR from baseline to 1 month in patients assigned to finerenone or placebo

